Serum free fatty acid levels in PCOS patients treated with glucophage, magnesium oxide and spironolactone

References

• Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745–9
   PubMed Web of Science ®Google Scholar
• Tehrani FR, Rashidi H, Azizi F. The prevalence of idiopathic hirsutism and polycystic ovary syndrome in the Tehran Lipid and Glucose Study. Reprod Biol Endocrinol 2011;9:144--51
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod 2004;19:41–7
   PubMed Web of Science ®Google Scholar
• Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165–74
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141–6
   PubMed Web of Science ®Google Scholar
• Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165–9
   PubMed Web of Science ®Google Scholar
• Muneyyirci-Delale O, Nacharaju VL, Dalloul M, et al. Divalent cations in women with PCOS: implications for cardiovascular disease. Gynecol Endocrinol 2001;15:198–201
   PubMed Web of Science ®Google Scholar
• Kao WH, Folsom AR, Nieto FJ, et al. Serum and dietary magnesium and the risk for type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Arch Intern Med 1999;159:2151–9
   PubMed Web of Science ®Google Scholar
• Boden G, She P, Mozzoli M, et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes 2005;54:3458–65
   PubMed Web of Science ®Google Scholar
• Bergman RN, Ader M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 2000;11:351–6
   PubMed Web of Science ®Google Scholar
• Boden G. Interaction between free fatty acids and glucose metabolism. Curr Opin Clin Nutr Metab Care 2002;5:545–9
   PubMed Web of Science ®Google Scholar
• Lam TK, van de Werve G, Giacca A. Free fatty acids increase basal hepatic glucose production and induce hepatic insulin resistance at different sites. Am J Physiol Endocrinol Metab 2003;284:E281–90
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhang J, Wen Y, et al. Increased acylation-stimulating protein, C-reactive protein, and lipid levels in young women with polycystic ovary syndrome. Fertil Steril 2009;91:213–9
   PubMed Web of Science ®Google Scholar
• Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000;85:139–46
   PubMed Web of Science ®Google Scholar
• Saha L, Kaur S, Saha PK. Pharmacotherapy of polycystic ovary syndrome – an update. Fundam Clin Pharmacol 2012;26:54–62
   PubMed Web of Science ®Google Scholar
• Garg R, Hurwitz S, Williams GH, et al. Aldosterone production and insulin resistance in healthy adults. J Clin Endocrinol Metab 2010;95:1986–90
   PubMed Web of Science ®Google Scholar
• Cascella T, Palomba S, Tauchmanovà L, et al. Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2006;91:4395–400
   PubMed Web of Science ®Google Scholar
• Kim DJ, Xun P, Liu K, et al. Magnesium intake in relation to systemic inflammation, insulin resistance, and the incidence of diabetes. Diabetes Care 2010;33:2604–10
   PubMed Web of Science ®Google Scholar
• Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res 1999;7:355–62
   PubMedGoogle Scholar
• Mejia-Montilla J, Reyna-Villasmil E, Torres-Cepeda D, et al. Plasma renin and aldosterone levels in obese and non-obese women with polycystic ovary syndrome. Endocrinol Nutr 2012;59:21–7
   PubMedGoogle Scholar
• Goodfriend TL, Egan BM, Kelley DE. Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids 1999;60:401–5
   PubMed Web of Science ®Google Scholar
• Wada T, Kenmochi H, Miyashita Y, et al. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology 2010;151:2040–9
   PubMed Web of Science ®Google Scholar
• Karakas SE, Almario RU, Kim K. Serum fatty acid binding protein 4, free fatty acids, and metabolic risk markers. Metabolism 2009;58:1001–7
   Web of Science ®Google Scholar
• Sacena P, Prakash A, Nigam A. Effect of metformin therapy on 2-h post-glucose insulin levels in patients of polycystic ovarian syndrome. J Hum Reprod Sci 2010;3:139–42
   PubMedGoogle Scholar
• Nestler JE. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 2008;358:47–54
   PubMed Web of Science ®Google Scholar
• Sheehan MT. Polycystic ovarian syndrome: diagnosis and management. Clin Med Res 2004;2:13–27
   PubMedGoogle Scholar
• Tang JZ, Mao JP, Yang ZF, et al. Effects of glimepiride and metformin on free fatty acid in patients with type 2 diabetes mellitus. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2004;29:631–4
   PubMedGoogle Scholar
• Li XM, Li Y, Zhang NN, et al. Combination therapy with metformin and fenofibrate for insulin resistance in obesity. J Int Med Res 2011;39:1876–82
   PubMed Web of Science ®Google Scholar
• Guerrero-Romero F, Rodríguez-Morán M. Magnesium improves the beta-cell function to compensate variation of insulin sensitivity: double-blind, randomized clinical trial. Eur J Clin Invest 2011;41:405–10
   PubMed Web of Science ®Google Scholar